Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20755340 | 0.77 | CHRM5 (0.46) | CHRM5ADRA2CACHESMN1; SMN2 | |
| SCHEMBL3637083 | 0.75 | CHRM5 (0.84) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL22810422 | 0.75 | CHRM5 (0.56) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL1564103 | 0.73 | CHRM5 (0.90) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL3611455 | 0.73 | CHRM5 (0.90) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL12714723 | 0.72 | CHRM5 (0.58) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL12716928 | 0.72 | CHRM5 (0.58) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL22699693 | 0.72 | CHRM5 (0.58) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL14508369 | 0.71 | CHRM5 (0.56) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL1827882 | 0.70 | CHRM5 (0.94) | CHRM5ADRA2CACHESMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019036384-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |